Description
Deucravacitinib is a Tyrosine Kinase 2 Inhibitor. The mechanism of action of deucravacitinib is as a Tyrosine Kinase 2 Inhibitor. Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis.